Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ascending-dose study of elritercept for anemia in lower-risk myelodysplastic syndromes
2023-507469-24-00Phase 2Authorised
- Sponsor
- Takeda
- Start
- Apr 2022
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 2, open-label trial of elritercept in myelodysplastic syndrome (MDS) (3 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability in Part 1 and Part 2 and Safety and tolerability in long-term extension. Planned start Apr 2022; status: authorised.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-507469-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507469-24-00.